{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:51:36Z","timestamp":1764172296835},"reference-count":32,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.3960\/jslrt.17020","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T22:10:07Z","timestamp":1507759807000},"page":"69-73","source":"Crossref","is-referenced-by-count":15,"title":["Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia"],"prefix":"10.3960","volume":"57","author":[{"given":"Minoru","family":"Kojima","sequence":"first","affiliation":[{"name":"Department of Hematology, Ebina General Hospital"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Tokai University School of Medicine"},{"name":"Department of Internal Medicine, Sangenjaya-daiichi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Amaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ebina General Hospital"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Numata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ebina General Hospital"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Miyaoka","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Motoori","sequence":"additional","affiliation":[{"name":"Sagamihara Soubudai Pathology Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ebina General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Campo E, Swerdlow SH, Harris NL, <i>et al<\/i>.: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117: 5019-5032, 2011"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Geary CG: The story of chronic myeloid leukaemia. Br J Haemtol 110: 2-11, 2000","DOI":"10.1046\/j.1365-2141.2000.02137.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Hoffmann VS, Baccarani M, Hasford J, <i>et al<\/i>.: Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia 31: 593-601, 2017","DOI":"10.1038\/leu.2016.246"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Quint\u00e1s-Cardama A, Kantarjian H, O\u2019brien S, <i>et al<\/i>.: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25: 3908-3914, 2007","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Kantarjian H, Shah NP, Hochhaus A, <i>et al<\/i>.: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270, 2010","DOI":"10.1056\/NEJMoa1002315"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Saglio G, Kim DW, Issaragrisil S, <i>et al<\/i>.: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259, 2010","DOI":"10.1056\/NEJMoa0912614"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Cortes JE, Kim DW, Kantarjian HM, <i>et al<\/i>.: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia results from the BELA trial. J Clin Oncol 30: 3486-3492, 2012","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Carbone A, Gloghini A: KSHV\/HHV8-associated lymphomas. Br J Haematol 140: 13-24, 2008","DOI":"10.1111\/j.1365-2141.2007.06879.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kobayashi Y, Kamitsuji Y, Kuroda J, <i>et al<\/i>.: Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature. Acta Haematol 117;132-144, 2007","DOI":"10.1159\/000097460"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Carbone A, Gloghini A: PEL and HHV8-unrelated effusion lymphomas classification and diagnosis. Cancer 114:225-227, 2008","DOI":"10.1002\/cncr.23597"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Takahashi N, Miura I, Saitoh K, Miura AB: Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence in situ hybridization. Blood 92: 4758-4763, 1998","DOI":"10.1182\/blood.V92.12.4758.424k35_4758_4763"},{"key":"12","unstructured":"12 Ichinohasama R, Miura I, Takahashi N, <i>et al<\/i>.: Ph-negative non-Hodgkin\u2019s lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. Leukemia 14(1): 169-182, 2000"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hochhaus A, Larson RA, Guilhot F , <i>et al<\/i>.: Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 376(10): 917-927, 2017","DOI":"10.1056\/NEJMoa1609324"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Cortes JE, Saglio G, Kantarjian HM, <i>et al<\/i>.: Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 34(20): 2333-2340. 2016","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kawamata T, Lu J, Sato T, <i>et al<\/i>.: Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor. Blood 119(13): 3123-3127. 2012","DOI":"10.1182\/blood-2011-01-327932"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Quint\u00e1s-Cardama A, Kantarjian H, O\u2019brien S, <i>et al<\/i>.: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25: 3908-3914, 2007","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Lombardo LJ, Lee FY, Chen P, <i>et al<\/i>.: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661, 2004","DOI":"10.1021\/jm049486a"},{"key":"18","unstructured":"18 Lee F, Lombardo, L, Camuso, A, <i>et al<\/i>.: BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities <i>in vitro<\/i> and <i>in vivo<\/i>. Proc Am Assoc Cancer Res 46: 159, 2005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Bergers G, Song S, Meyer-Morse N, <i>et al<\/i>.: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295, 2003","DOI":"10.1172\/JCI17929"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Hellstrom M, Kalen M, Lindahl P, <i>et al<\/i>.: Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126: 3047-3055, 1999","DOI":"10.1242\/dev.126.14.3047"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Lindahl P, Johansson BR, Leveen P, <i>et al<\/i>.: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-245, 1997","DOI":"10.1126\/science.277.5323.242"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Jayson GC, Parker GJ, Mullamitha S, <i>et al<\/i>.: Blockade of platelet-derived growth factor receptor beta by CDP860, a humanized, PEGylated di-Fab\u2019, leads t o fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23: 973-981, 2005","DOI":"10.1200\/JCO.2005.01.032"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Goldsby R, Pulsipher M, Adams R, <i>et al<\/i>.: Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J Pediatr Hematol Oncol 24: 694-695, 2002","DOI":"10.1097\/00043426-200211000-00020"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Park YH, Park HJ, Kim BS, <i>et al<\/i>.: BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 243:16-22, 2005","DOI":"10.1016\/j.canlet.2005.11.014"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Breccia M, D\u2019Elia GM, D\u2019Andrea M, <i>et al<\/i>.: Pleural-pericardic effusion as uncommon complication in CML patients treated with imatinib. Eur J Haematol 74: 89-90, 2005","DOI":"10.1111\/j.1600-0609.2004.00347.x"},{"key":"26","unstructured":"26 Carragher NO, Westhoff MA, Fincham VJ, <i>et al<\/i>.: A novel role for FAK as a protease-targeting adaptor protein: Regulation by p42 ERK and Src. Curr Biol 13: 1442-1450, 2003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Carragher NO, Frame MC: Calpain: A role in cell transformation and migration. Int J Biochem Cell Biol 34: 1539-1543, 2002","DOI":"10.1016\/S1357-2725(02)00069-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Luton F, Verges M, Vaerman JP, <i>et al<\/i>.: The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis <i>in vivo<\/i>. Mol Cell 4: 627-632, 1999","DOI":"10.1016\/S1097-2765(00)80213-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513-609, 1999","DOI":"10.1146\/annurev.cellbio.13.1.513"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Abram CL, Courtneidge SA: Src family tyrosine kinases and growth factor signaling. Exp Cell Res 254: 1-13, 2000","DOI":"10.1006\/excr.1999.4732"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Cortes J, Kantarjian, H, Baccarani, M, <i>et al<\/i>.: A phase 1\/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 108, 2006 (abstr 168)","DOI":"10.1182\/blood.V108.11.168.168"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Puttini M, Coluccia AM, Boschelli F, <i>et al<\/i>.: <i>In vitro<\/i> and <i>in vivo<\/i> activity of SKI-606, a novel Src-Abl inhibitor, against imatinibresistant Bcr-Abl+ neoplastic cells. Cancer Res 66: 11314-11322, 2006","DOI":"10.1158\/0008-5472.CAN-06-1199"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/57\/2\/57_17020\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T09:08:46Z","timestamp":1659604126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/57\/2\/57_17020\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.17020","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}